Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

PHASE3CompletedINTERVENTIONAL

Enrollment

146

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

February 29, 2020

Study Completion Date

February 29, 2020

Conditions

Chronic Hepatitis B

Interventions

DRUG

Besifovir 150mg

Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.

DRUG

Tenofovir 300mg

Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.

Trial Locations (1)

Severance Hospital of Yonsei University, Seoul